These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 2318702)

  • 21. Dosimetry and physical treatment planning for iodine eye plaque therapy.
    Alberti W; Pothmann B; Tabor P; Muskalla K; Hermann KP; Harder D
    Int J Radiat Oncol Biol Phys; 1991 May; 20(5):1087-92. PubMed ID: 2022510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delivered dose uncertainty analysis at the tumor apex for ocular brachytherapy.
    Morrison H; Menon G; Larocque MP; Jans HS; Weis E; Sloboda RS
    Med Phys; 2016 Aug; 43(8):4891. PubMed ID: 27487906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved treatment planning for COMS eye plaques.
    Astrahan MA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1227-42. PubMed ID: 15752905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental validation of a new COMS-like 24 mm eye plaque for the treatment of large ocular melanoma tumors.
    McCauley Cutsinger S; Forsman R; Corner S; Deufel CL
    Brachytherapy; 2019; 18(6):890-897. PubMed ID: 31444131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An improved treatment planning and quality assurance process for Collaborative Ocular Melanoma Study eye plaque brachytherapy.
    Weersink RA; Patterson S; Ballantyne H; Di Tomasso A; Borg J; Vitkin A; Rink A; Beiki-Ardakani A
    Brachytherapy; 2019; 18(5):658-667. PubMed ID: 31235445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incorporating patient-specific CT-based ophthalmic anatomy in modeling iodine-125 eye plaque brachytherapy dose distributions.
    Tien CJ; Astrahan MA; Kim JM; Materin M; Chen Z; Nath R; Liu W
    Brachytherapy; 2017; 16(5):1057-1064. PubMed ID: 28778599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function.
    Gagne NL; Leonard KL; Rivard MJ
    Med Phys; 2012 Jun; 39(6):3332-42. PubMed ID: 22755715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transitioning from a COMS-based plaque brachytherapy program to using eye physics plaques and plaque simulator treatment planning system: A single institutional experience.
    Meltsner SG; Rodrigues A; Materin MA; Kirsch DG; Craciunescu O
    J Appl Clin Med Phys; 2023 May; 24(5):e13902. PubMed ID: 36637797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models.
    Thomson RM; Rogers DW
    Med Phys; 2010 Jan; 37(1):368-76. PubMed ID: 20175499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Model-based dose calculations for COMS eye plaque brachytherapy using an anatomically realistic eye phantom.
    Lesperance M; Inglis-Whalen M; Thomson RM
    Med Phys; 2014 Feb; 41(2):021717. PubMed ID: 24506608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EyeDose: An open-source tool for using published Monte Carlo results to estimate the radiation dose delivered to the tumor and critical ocular structures for
    Deufel CL; McCauley Cutsinger S; Corbin KS; Dalvin LA; Petersen IA
    Brachytherapy; 2021; 20(1):189-199. PubMed ID: 33187821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ROPES eye plaque brachytherapy dosimetry for two models of (103)Pd seeds.
    Saidi P; Sadeghi M; Shirazi A; Tenreiro C
    Australas Phys Eng Sci Med; 2011 Jun; 34(2):223-31. PubMed ID: 21452056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
    Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
    Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COMS eye plaque brachytherapy dosimetry simulations for 103Pd, 125I, and 131Cs.
    Melhus CS; Rivard MJ
    Med Phys; 2008 Jul; 35(7):3364-71. PubMed ID: 18697560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement of dose distribution in ocular brachytherapy with
    Zabihzadeh M; Rezaee H; Hosseini SM; Feghhi M; Danyaei A; Hoseini-Ghahfarokhi M
    J Cancer Res Ther; 2019; 15(3):504-511. PubMed ID: 31169211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of material heterogeneity dosimetric effects using radiochromic film for COMS eye plaques loaded with (125)I seeds (model I25.S16).
    Acar H; Chiu-Tsao ST; Ozbay I; Kemikler G; Tuncer S
    Med Phys; 2013 Jan; 40(1):011708. PubMed ID: 23298078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. I-125 ROPES eye plaque dosimetry: validation of a commercial 3D ophthalmic brachytherapy treatment planning system and independent dose calculation software with GafChromic® EBT3 films.
    Poder J; Corde S
    Med Phys; 2013 Dec; 40(12):121709. PubMed ID: 24320495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 106Ru/106Rh plaque and proton radiotherapy for ocular melanoma: a comparative dosimetric study.
    Mourtada F; Koch N; Newhauser W
    Radiat Prot Dosimetry; 2005; 116(1-4 Pt 2):454-60. PubMed ID: 16604677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The design and the dosimetry of bi-nuclide radioactive ophthalmic applicators.
    Flühs D; Anastassiou G; Wening J; Sauerwein W; Bornfeld N
    Med Phys; 2004 Jun; 31(6):1481-8. PubMed ID: 15259651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delivered dose changes in COMS plaque-based ocular brachytherapy arising from vitrectomy with silicone oil replacement.
    Morrison H; Larocque MP; Menon G; Sloboda RS; Weis E
    Brachytherapy; 2019; 18(5):668-674. PubMed ID: 31272841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.